



Early gene expression analysis in 9L orthotopic tumor-bearing rats identifies immune modulation in molecular response to synchrotron microbeam radiation therapy.

Audrey Bouchet, Nathalie Sakakini, Michèle El Atifi, Céline Le Clec'H, Elke Brauer, Anaïck Moisan, Pierre Deman, Pascal Rihet, Géraldine Le Duc, Laurent Pelletier

► To cite this version:

Audrey Bouchet, Nathalie Sakakini, Michèle El Atifi, Céline Le Clec'H, Elke Brauer, et al.. Early gene expression analysis in 9L orthotopic tumor-bearing rats identifies immune modulation in molecular response to synchrotron microbeam radiation therapy.. PLoS ONE, Public Library of Science, 2013, 8 (12), pp.e81874. <10.1371/journal.pone.0081874>. <inserm-00955553>

HAL Id: inserm-00955553

<http://www.hal.inserm.fr/inserm-00955553>

Submitted on 4 Mar 2014

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Early Gene Expression Analysis in 9L Orthotopic Tumor-Bearing Rats Identifies Immune Modulation in Molecular Response to Synchrotron Microbeam Radiation Therapy

Audrey Bouchet^{1,2*}, Nathalie Sakakini^{4,5}, Michèle El Atifi^{1,3}, Céline Le Clec'h², Elke Brauer², Anaïck Moisan⁶, Pierre Deman⁷, Pascal Rihet^{4,5}, Géraldine Le Duc², Laurent Pelletier^{1,3*}

1 Institut National de la Santé et de la Recherche Médicale (INSERM) - Unit 836, Team Nanomedicine and brain, La Tronche, France, **2** European Synchrotron Radiation Facility (ESRF), Biomedical Beamline, Grenoble, France, **3** Grenoble University Hospital, Grenoble, France, **4** Unité Mixte de Recherche 1090, Team Technological Advances for Genomics and Clinics (TAGC), Institut National de la Santé et de la Recherche Médicale (INSERM), Marseille, France, **5** Aix-Marseille Université, Marseille, France, **6** Institut National de la Santé et de la Recherche Médicale (INSERM) - Unit 836, Team Functional Neuroimaging and Brain Perfusion, La Tronche, France, **7** Institut National de la Santé et de la Recherche Médicale (INSERM) - Unit 836, Team Synchrotron Radiation and Medical Research, La Tronche, France

Abstract

Synchrotron Microbeam Radiation Therapy (MRT) relies on the spatial fractionation of the synchrotron photon beam into parallel micro-beams applying several hundred of grays in their paths. Several works have reported the therapeutic interest of the radiotherapy modality at preclinical level, but biological mechanisms responsible for the described efficacy are not fully understood to date. The aim of this study was to identify the early transcriptomic responses of normal brain and glioma tissue in rats after MRT irradiation (400Gy). The transcriptomic analysis of similarly irradiated normal brain and tumor tissues was performed 6 hours after irradiation of 9 L orthotopically tumor-bearing rats. Pangenomic analysis revealed 1012 overexpressed and 497 repressed genes in the irradiated contralateral normal tissue and 344 induced and 210 repressed genes in tumor tissue. These genes were grouped in a total of 135 canonical pathways. More than half were common to both tissues with a predominance for immunity or inflammation (64 and 67% of genes for normal and tumor tissues, respectively). Several pathways involving HMGB1, toll-like receptors, C-type lectins and CD36 may serve as a link between biochemical changes triggered by irradiation and inflammation and immunological challenge. Most immune cell populations were involved: macrophages, dendritic cells, natural killer, T and B lymphocytes. Among them, our results highlighted the involvement of Th17 cell population, recently described in tumor. The immune response was regulated by a large network of mediators comprising growth factors, cytokines, lymphokines. In conclusion, early response to MRT is mainly based on inflammation and immunity which appear therefore as major contributors to MRT efficacy.

Citation: Bouchet A, Sakakini N, El Atifi M, Le Clec'h C, Brauer E, et al. (2013) Early Gene Expression Analysis in 9L Orthotopic Tumor-Bearing Rats Identifies Immune Modulation in Molecular Response to Synchrotron Microbeam Radiation Therapy. *PLoS ONE* 8(12): e81874. doi:10.1371/journal.pone.0081874

Editor: Fabrizio Mattei, Istituto Superiore di Sanità, Italy

Received: July 1, 2013; **Accepted:** October 19, 2013; **Published:** December 31, 2013

Copyright: © 2013 Bouchet et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the French National Institute of Health and Medical Research INSERM (U836), European Synchrotron Radiation Facility and Institut National du Cancer (INCa - Bioresis program). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: laurent.pelletier@ujf-grenoble.fr

‡ Current address: Institute of Anatomy, Bern, Switzerland

Introduction

Glioblastoma is the most aggressive form of brain tumor. Despite the improvements in therapy [1] the median survival of patients is around 12–15 months after diagnosis with a poor survival rate of 9.8% beyond 5 years.

Synchrotron microbeam radiation therapy (MRT), a new form of radiosurgery, has been applied to rodent brain tumors and composed a new hope of treatment [2,3]. The use of highly intense synchrotron X-ray beams, with a high energy, high flux and a negligible divergence allows spatial fractionation of an incident beam into arrays of few tens microns wide parallel microbeams, delivering high radiation doses (hGy) in their paths and separated by few hundred microns wide [4].

MRT protocol performed on the brains of adult rats [5], suckling rats [6], ducks embryos [7] and piglets [8] highlighted a sparing effect on normal tissues and can reduce the growth or

ablate EMT6 carcinoma [9], SCCVII carcinoma [10] and 9 L intracerebral glioma [6,11–13].

It has been shown that the sparing effect is supported by the radioresistance of normal brain vessels to MRT for doses up to 1,000Gy [14,15], while there is a denudation of the tumor endothelium and a decrease in tumor blood volume [16,17]. Beyond the involvement of the vascular component, it has been suggested that other processes were also responsible for tumor control [17,18] and remain to be described and understood. Besides, the effects of MRT have been studied at *in vivo*, histological or cellular levels, but few information deals with molecular mechanisms. Due to the unique irradiation geometry and the extraordinary dose delivered by MRT, it is not reasonable to extrapolate data and biological molecular events from conventional radiotherapy studies without prior studies.

Describing the early molecular events after MRT could complete the understanding of the normal and tumor tissue response to this particular irradiation. Microarray gene expression technology allows simultaneous analysis of the expression levels of thousands of genes [19]. It has been extensively used to describe the response of biological entity to treatment, to assess genes involved in resistance to therapy and to identify therapeutic targets [20].

The purpose of this work was to characterize the early transcriptomic responses of 9 L tumor and normal brain tissues (contralateral half hemisphere) after a lateral unidirectional MRT exposure (using 50 microns wide microbeams of 400Gy at the tumor location, separated by 200 microns center-to-center). We first illustrated the effectiveness of this single irradiation on the survival of animals. Then, we used oligonucleotide microarray containing 31,100 probe sets (28,000 genes) to acquire the transcriptomic response of both 9 L glioma and contralateral hemisphere 6 h after irradiation. Ingenuity Pathway Analysis software allowed to underline biological functions and canonical pathways involved in MRT response.

Materials and Methods

Ethics, animal care and study design

All procedures related to animal care conformed to the Guidelines of the French Government under licenses 380325 and B3818510002 and were approved by the ESRF internal ethics committee named “Internal Evaluation Committee for Animal Welfare and Rights” (IECAWR). The committee specifically approved this study.

All animals were Fischer male rats (Charles River, France) of 8 week-old at arrival. The 9 L cells were implanted one week after the rat arrival (D0), and rats were allocated in two equilibrated groups according tumor size measured using MRI 9 days after implantation (D9). Rats were irradiated 10 days after implantation (D10). The control animals (i.e. non-irradiated) were implanted in common for two experiments including this one, in order to reduce the number of animals.

First, two groups of rats were MRT-treated ($n=20$) or not ($n=9$) and their survival was measured. Rats were observed and weighted twice a week. They were humanely euthanized (intracardiac injection of pentobarbital after isoflurane inhalation) when previously defined clinical criteria were met (prostration, akinesy, epistaxis, rotational motion, 25% body weight loss). In the second part of the study aimed to define the molecular response to MRT, two independent but similar experiments were performed: rats were MRT-treated ($n=5$ and $n=5$) or not ($n=4$ and $n=5$) and euthanized after 6 h for brain excision.

Rats were anesthetized with a shot of isoflurane 5% in air prior to an intraperitoneal injection of xylazine/ketamine 64.5/5.4 mg.kg⁻¹ for the implantation procedure (and local anesthesia was performed by administration of lidocaine at the top of the scalp) while they were maintained only under isoflurane 2.5% for MRI examination and MRT irradiation. Ocry-gel (Carbopol) was applied to avoid eye deshydration during any anesthesia.

Tumor implantation

The 9 L cells [20] were grown with complete medium (DMEM/Fetal bovin serum 10%/Penicillin and Streptavidin 1%) at 37°C in a humidified 5% CO₂ incubator. As previously described [21], anesthetized Fischer rats were placed on a stereotactic head holder. Then 10⁴ 9 L cells in 1 μL DMEM were injected using a Hamilton syringe into the right caudate

nucleus (9 mm anterior to the ear-bars i.e. at *bregma* site, 3.5 mm lateral to the midline, 5.5 mm depth from the skull).

Tumor MRI examination and rat randomization

Nine days after 9 L implantation, all rats underwent anatomical MRI examination in order to sort them two groups with similar mean tumor size. MRI was performed at 4.7 Tesla or 7 Tesla (Avance III console; Bruker) of the Grenoble IRMaGe MRI facility, using a horizontal magnet and a volume/surface cross coil configuration applying a T₂ weighted Turbo RARE SE sequence (TE = 33 ms, TR = 4000 ms, field of view = 3 × 3 cm, matrix: 256 × 256, slice thickness = 1 mm). The height and width of tumors were measured on the image where the signal modification due to edema and tumor had the largest section. The 3rd direction was estimated by counting the slices displaying the tumor.

MRT irradiation

Irradiations were performed at the ID17 Biomedical Beamline of the European Synchrotron Radiation Facility (ESRF, France) using X-rays emitted tangentially from electron bunches circulating in a storage ring. The wiggler produces a wide spectrum of photons which extends, after filtration, from 50 over 350 keV (median energy: 90 keV) [22]. The mean dose rate was then ~62Gy.mA⁻¹.s⁻¹ allowing very fast irradiation. The quasi-laminar beam was micro-fractionated into an array of 41 rectangular and quasi-parallel 50 microns width microbeams, separated by 200 microns center to center each. This was performed by using the ESRF Multislit Collimator positioned 33 m from the photon source and 80 cm upstream from the rat holder [23]. Ten days after tumor inoculation, the animals were positioned prone on a Kappa-type goniometer (Huber, Germany) in front of the x-rays source, on a home-made plexiglas frame and the alignment into the beam was performed using live cameras. The contention of the rats was performed by a teeth bar while the animals were under anesthesia. They were placed perpendicularly to the beam and received a lateral irradiation, from their anatomical right to left side. The beam was shaped into a field of irradiation of 8 mm horizontal and the animals were scanned vertically over 10 mm through the beam after opening of the shutter. Although the total procedure lasted about 2 min for each rat, the irradiation time is around to 2 s. Animal immobility during exposure was checked on three control video screens located in the control hut.

Dosimetry and ballistic of irradiation

The microbeam dose at the tumor (i.e. 7 mm of depth from lateral side) was 400Gy, the valley dose was 18 ± 0.6Gy as computed by Monte Carlo simulations [24]. The spatial configuration of irradiation was checked by radiochromic films (Gafchromic, HD-810) exposed in front of rats. The conservation of spatial configuration in tumor depth was checked by pH2AX staining (double strand break indirect staining) on tissue sections 6 h after irradiation.

Survival curves

Kaplan Meier survival data of 9 untreated rats and 20 treated rats was plotted versus time after tumor implantation. Median Survival Time (MST) and statistical analysis (log rank test) were performed using GraphPad Software, USA.

Brain excision

Untreated and MRT-treated rats (respectively $n=10$ and $n=9$) were sacrificed 6 h after irradiation, and the brain of each animal

was immediately frozen in liquid isopentane at -50°C and stored at -80°C .

Total RNA extraction and quality control

For each brain, 25 coronal sections slices of $60\ \mu\text{m}$ thick were cut at -20°C on a cryostat (Microm HM80, France). The tumors and the contralateral tissues were isolated using a micropunch and kept in lysis RNase free buffer from the MirVana isolation kitTM (Ambion, Applied Biosystems, Foster City, CA).

Total RNA of each tissue was extracted with the previous kit according to specifications. RNA integrity and concentration were checked by Agilent NanoRNA Chip (Bio-Analyser, Agilent Technologies, Palo Alto, CA, USA). A minimum RNA Integrity Number of 7.6 was required for all samples.

RNA microarray

Microarray analysis were performed on total RNA of brain of untreated ($n=5$) and MRT-treated groups ($n=6$) from two experimental sessions (Figure 1). For each sample, 200 ng of total RNA was amplified with the GeneChip 3'IVT Express Kit (Affymetrix, Santa Clara, CA) and hybridized on GeneChip[®] Rat Genome 230 2.0 Array according to Affymetrix specifications. Briefly, mRNAs were reverse transcribed to double stranded cDNA, amplified, fragmented and biotin-labelled. End-label cDNA were hybridized to microarray chip for 16 h at 45°C and 60rpm. After washing and staining in Affymetrix GeneChip[®] Fluidics Station 450, microarrays were scanned using Affymetrix GeneChip[®] Scanner 3000. Light emission at 570 nm is proportional to each oligonucleotide amount on the GeneChip[®] array.

Gene expression normalization

Background adjustment and normalization of all raw probe intensity were performed using the Robust Multi-array Average (RMA) algorithm [25] implemented in Affymetrix Expression Console. The expression values were reported in arbitrary units. Moreover, the MicroArray Suite 5 (MAS5) algorithm [26] was used on raw data to identify probe sets which were out of the limit of detection for the system and to flag the transcript as Present (P) or Absent (A). P- and A-flagged information was used to filter data in order to remove false positive after statistical analysis.

Statistical analysis of microarray data

Statistical analysis was performed using the TIGR Multi-Experiment Viewer version 4.5.1 software (TMeV, <http://www.tm4.org/mev/>). Significant differentially expressed genes between the two tumor groups and between the two contralateral tissue groups (MRT treated or not) obtained 6 h after irradiation were assessed using an unpaired Significance Analysis of Microarrays (SAM) [27]. A False-Discovery Rate (FDR) lower than 5% was

fixed to generate significant genes list. Hierarchical clustering was directly generated thanks to TMeV from this list. For all other analyses, probes were only considered when at least $n-1$ values were P-flagged (MAS5) in any of both compared groups.

Functional analysis

The molecular & cellular functions and canonical pathways associated with differentially expressed genes identified by SAM test (FDR 5%) and P/A flag filtered were identified thanks to Ingenuity Pathways Analysis (IPA) software (Ingenuity[®] Systems, www.ingenuity.com). The data set was restricted to mammal species.

Molecules from the data set were associated with the most relevant “molecular & cellular functions” and “canonical pathways” in the Ingenuity Knowledge Base. The significance of the association between the data set and the bio-function or the canonical pathways was measured in 2 ways: 1) a ratio between the number of molecules for a given function or pathway issued from the data set and the total number of molecules for the same function or pathway is displayed. 2) Right-tailed Fisher's exact test was used to calculate a p-value determining the probability that each function or pathway assigned to that data set was due to the chance alone. For canonical pathways, a false discovery rate of 1% was further applied to correct for multiple testing [28,29].

RT-qPCR transcriptional validation for genes regulated 6 h after MRT

Some selected significantly up- and down-regulated genes were validated using reverse transcription and quantitative polymerase chain reaction (RT-qPCR) on untreated and MRT-treated tumor samples ($7 < n < 10$, depending on sample availability).

Two micrograms of total RNA were transcribed into cDNA using Promega Reverse Transcription reagents with random dN6 primers. Specific gene primers (Table 1) were designed using software (<https://www.roche-applied-science.com/sis/rtqcr/upl/ezhome.html>). Real-time PCR were performed according to the SYBR Green method on an Mx3000TM apparatus (Stratagene, La Jolla, CA) using Quantitect SYB[®] reagents (Qiagen, France). Data were normalized using two housekeeping genes, Atp5b and Arpc1a, selected according to Affymetrix data because of both their suitable range of quantification and very low variation in expression levels across all samples (8% and 7%, respectively). Thermal-cycling parameters were as follows: denaturation at 95°C for 10 min, cycling regime of 40 cycles at 95°C for 15 s, 56°C for 30 s, and 72°C for 30 s.

Results

Survival

In order to obtain similar irradiation in tumor and normal contralateral brain tissue, we have adapted a configuration of MRT previously reported to have a high interest for 9 L brain tumors therapy [17]. As shown in figure 2, this unilateral MRT irradiation significantly increased the Mean Survival Time (MST) of treated animals compared with the untreated group (33 versus 19 days respectively, $p < 0.0001$).

Identification of early gene response in 9 L tumor and contralateral brain tissue

Six hours after irradiation, we observed (i) a modification of transcriptomic profiles in both tissues and (ii) a difference in responses of tumor and contralateral tissues (Figure 3a and b). Indeed, 1,509 genes (1,012 were induced and 497 were inhibited)




Figure 1. Experimental scheme. Contralateral normal and tumor tissue samples were irradiated (MRT) or not (untreated) in 2 experimental sessions (S_1 and S_2). The transcriptomic data were compared in order to determine contralateral normal and tumor tissue responses to MRT (Δ normal tissue or Δ tumor tissue). doi:10.1371/journal.pone.0081874.g001

Table 1. Validation gene set.

Symbol	Gene Name	Forward (5'-3')	Reverse Primer (5'-3')
Arpc1a	actin related protein 2/3 complex, subunit 1A	gtttgctgtggggagtg	ggatcggtcttctaatgtc
Atp5b	ATP synthase, H ⁺ transporting, mitochondrial F1 complex, beta polypeptide	gggtacaatgcagga	tcagctggcacatag
Fam64a	family with sequence similarity 64, member A	gaagctgtctcaaagctgga	aaggagacggtcatgtcac
Inhbe	inhibin beta E	caggcagcactgaccaga	cggtaggtggaagtggatt
Mars	mehionine-tRNA synthetase	atacgttcggtcgacaac	gcaaccttgaagatgtcc
Traf4af1	TRAF4 associated factor 1	cggaggaaatcagaagcag	gctcgtttttatccttcagatcc
Pttg1	pituitary tumor-transforming 1	ttctccccttcgatcctct	aggggagaagtggatctggt
Trib3	tribbles homolog 3b	tcaagttcgtcgattgtc	ccagtcacacagggcatc

List of the genes with significant up- or down-regulation which were selected for microarray data validation using RT-qPCR. Primer sequences for quantitative RT-qPCR are indicated in the two right-hand columns.

doi:10.1371/journal.pone.0081874.t001

and 554 genes (344 were induced and 210 were inhibited) significantly responded to MRT in tumor and contralateral tissues, respectively (Figure 3c and Table S1). Figures 3a and 3b show the clustering analysis based on the selected genes in contralateral and tumor tissues respectively. Among them, 319 were common to both tissues as represented on Venn diagram (227 were induced and 92 were inhibited).

Validation of gene expression modulation by RT-qPCR

We validated the variation of gene expression by quantitative RT-PCR on 6 representative genes with significant expression modulation in tumor. RT-qPCR analysis was performed on tissues that had been already analyzed on microarray and extended on supplementary tumors (in all $n \geq 7$). The RT-qPCR results confirmed that expression of all selected genes was significantly different between treated and untreated tumors ($p < 0.05$, permutation t-test) and were therefore consistent with those obtained by microarrays (Figure 4).

Identification of biological functions modulated in 9 L tumor and contralateral brain tissues 6 hours after MRT

Genes identified by SAM analysis with a 5% FDR were classified into different bio-function categories based on IPA




Figure 2. Kaplan-Meier representation of tumor-bearing rat survival. Intracerebral 9 L rats were MRT-irradiated (solid black line) or not (dashed grey line). MRT significantly increased the Median Survival Time of animals compared with untreated rats (33 days *versus* 19 days, log rank test: $p < 0.0001$).

doi:10.1371/journal.pone.0081874.g002

database (Figure 5). The response to MRT irradiation involved 22 and 18 molecular and cellular functions in tumor and normal brain tissues, respectively. All functions found in contralateral tissue were also represented in tumor tissue. Some bio-function categories such as cell death, growth, proliferation, cell cycle, cellular function and maintenance can contribute to cell response to radiation-induced damages. Inflammation and immunity reaction appeared as a common point of cellular movement, antigen presentation and cell-to-cell signaling/interaction categories. Despite a lower number of genes per group, tumor response to MRT displayed four supplemental bio-functions compared to normal tissue: amino acid metabolism ($p = 7.02e^{-06}$), carbohydrate metabolism ($p = 2.44e^{-05}$), drug metabolism ($p = 7.02e^{-06}$) and nucleic acid metabolism ($p = 4.55e^{-06}$). These 4 bio-functions showed the lowest p-value obtained for MRT response in tumor (Figure 5).

Identification of pathways modulated in 9 L tumor and contralateral brain tissues 6 hours after MRT

Genes modulated 6 hours after MRT in tumor and contralateral tissues were grouped in canonical pathways (Table S2). Three statistical stringency levels were applied to data with 5, 1 and 0.1% of False Discovery Rate (FDR), corresponding to p-values lower to $1.62E-2$, $2.57E-3$ and $1.45E-4$ respectively. The number of pathways ranged from 83 (FDR0.1%) to 165 (FDR5%) in contralateral brain, from 36 to 100 in tumor and from 86 to 170 when both tissues were considered together. Pathways were more numerous for brain than for tumor (> 1.6), as already observed for modulated genes. For all FDRs, more than half of all pathways were found in both tissues (55.3% for FDR5%, 50.4% for FDR1% and 73.3% for FDR0.1%). So the response to MRT appeared to mainly involve similar mechanisms in normal brain and tumor. More, whatever the tissue or the FDR, pathways related to immunity or inflammation represented more than 55% of the total (from 55.8 for brain and tumor tissue with FDR5% to 74.4% for brain and tumor tissue with FDR0.1%). Thus the response to MRT was mainly based on these two processes. The pathways related to immunological or inflammatory responses were enriched in the most stringent statistical conditions, illustrating that these pathways are among the most significant ones.

We focused analysis on pathways with FDR1%. Genes modulated by MRT were grouped on 128 pathways in normal brain, 73 in tumor and 67 were common to both tissues. Among them, 82 and 49 pathways were related to immunity or




Figure 3. Influence of MRT on gene expression in tumor and contralateral brain tissues. a, b- Heat map showing either significant decrease or increase in mRNA expression after MRT in tumor and normal brain tissues. Colors indicate expression levels above (red) or below (green) the median value for each gene. Vertical columns indicate individual arrays and horizontal rows indicate genes. c- Venn diagrams showing the numbers of significantly increased (red) or decreased (green) genes after MRT in both tissues. doi:10.1371/journal.pone.0081874.g003




Figure 4. Validation of microarray analysis by quantitative RT-PCR on tumor tissue samples. Data were first normalized to the expression of Arpc1 and Atp5b housekeeping genes. The fold changes (\pm SEM) in each gene expression was calculated using the mean expression in treated ($n=6$ for microarray and $n=8$ to 9 for RT-qPCR) versus untreated ($n=5$ for microarray and $n=7$ to 10 for RT-qPCR) tumors 6 h after MRT. Fold changes are indicated below the histograms (several fold changes were available for microarray because of the presence of several probesets). All tested genes presented a significant difference between treated and untreated tissues ($p<0.05$; permutation t-test). doi:10.1371/journal.pone.0081874.g004




Figure 5. Molecular and cellular functions constituting the MRT response. Genes with a significantly modified expression in brain or tumor 6 hours after MRT were clustered in molecular and cellular function using IPA software. Number of genes and p-values ($-\log(\text{p-value})$) are illustrated for each function. The p-values associated with brain (dark blue) and tumor (light blue) are represented using histogram in the right-hand column. The p-values were calculated using the right-tailed Fisher’s exact test in IPA. doi:10.1371/journal.pone.0081874.g005

inflammation in normal brain and tumor respectively. Forty six immune-related pathways were common to both tissues; however they could include different genes for tumor and contralateral tissues (Figure 5).

All domains of innate and adaptive immunity were found in common canonical functions: macrophages (“Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis”, “Production of Nitric Oxide and Reactive Oxygen Species in Macrophages”, “IL-12 Signaling and Production in Macrophages”), natural killer cells (NK, “Crosstalk between Dendritic Cells and Natural Killer Cells”), dendritic cells (“Dendritic Cell Maturation”, “Crosstalk between Dendritic Cells and Natural Killer Cells”), T lymphocytes (“Altered T Cell and B Cell Signaling in Rheumatoid Arthritis”, “iCOS-iCOSL Signaling in T Helper Cells”, “4-1BB Signaling in T Lymphocytes”) and B lymphocytes (“Altered T Cell and B Cell Signaling in Rheumatoid Arthritis” and “B Cell Receptor Signaling”, “PI3K Signaling in B

Lymphocytes”, “B Cell Activating Factor Signaling”). Many canonical pathways and especially those centered on cytokines signaling, evoked also the immune network: Interleukins 1, 6, 8, 9, 10, 12, 15, 17A and 17F were found in 13 pathways. Immune cell communication was illustrated by other either mediators or receptors: TNF (“TWEAK Signaling”, “April Mediated Signaling”, “4-1BB signaling in T Lymphocytes”), Interferon (“Role of PKR in Interferon Induction and Antiviral Response”, “Role of JAK1, JAK2 and TYK2 in Interferon signaling”) and others (“iCOS-iCOSL Signaling in T Helper Cells”, “MIF Regulation of Innate Immunity”, “CD40 Signaling”). As expected, inflammation was found (“Acute Phase Response Signaling”, “TREM1 Signaling”, “Atherosclerosis Signaling”, “Role of IL-17F in Allergic Inflammatory Airway Diseases”, “Pathogenesis of Multiple Sclerosis”, “Role of IL-17A in Arthritis”, “MIF-mediated Glucocorticoid Regulation”, “Glucocorticoid Receptor Signaling”).

The common response to MRT comprised also modifications in the expression of genes involved in other mechanisms: Cell cycle, cell growth, apoptosis (“Induction of Apoptosis by HIV1”, “Apoptosis Signaling”, “Death Receptor Signaling”, “p38 MAPK Signaling”, “p53 Signaling”, “PI3K/AKT Signaling”), DNA damage sensing and repairing (“ATM Signaling”) and vascular physiology or angiogenesis (“Erythropoietin Signaling”, “Renin-Angiotensin Signaling”, “Angiopoietin Signaling”).

In normal brain, other pathways for cell cycle/growth or apoptosis (“Cell Cycle Regulation by BTG Family Proteins”, “ERK/MAPK Signaling”, “PTEN Signaling”), DNA damage sensing or repairing (“Role of BRCA1 in DNA Damage Response”) and vascular physiology and angiogenesis (“Role of Tissue Factor in Cancer”) were found.

Of interest, in tumor tissue, we found one pathway associated with both DNA damage and cell cycle regulation (“Cell Cycle: G2/M DNA Damage Checkpoint Regulation”).

A part of pathways were found in only one tissue. Concerning normal brain, a high proportion of pathways related to T-cells (15/49) was observed in comparison with those found in both tissues (6/46). On the opposite, only 4 pathways were preferentially associated with innate immunity in normal brain tissue.

Discussion

In this work we characterized the transcriptomic responses of tumor and normal brain tissues 6 hours after an MRT irradiation. A suitable model should heed following parameters: both tissues should originate from the same species in order to use a unique microarray type for transcriptome analysis, and host animal should be immunocompetent for considering the influence of the immune system. The 9 L tumors orthotopically implanted in syngeneic Fisher rat brain fulfill these conditions [20,30].

MRT has already been demonstrated as a promising irradiation modality for brain tumors therapy at preclinical level. Although MRT crossfire irradiation, the most efficient configuration for improving survival to date [6], implies that the tumor and the contralateral brain tissues are not treated the same way. We chose therefore a simpler configuration with a lateral unidirectional MRT irradiation in order to apply similar irradiation configuration in both tissues. This 400Gy in-microbeam dose scheme, applied to rat brain 10 days after tumor inoculation, significantly increased ($\times 1.7$) the median survival time (MST) compared to untreated rats (Figure 2). The set parameters enable then a rigorous analysis of biological mechanisms of MRT impact in both tumor and normal brain tissue responses. Although several studies already aimed at the understanding of biological processes induced by MRT, they were essentially based on late events (from 48 h post-MRT) [16,17]. In this work we focused on early response, assuming that early transcriptomic events would dictate later modifications at molecular, cellular, tissular and finally therapeutic levels. We considered also the particular lack of knowledge concerning MRT-associated biology at transcriptomic level.

MRT differs from conventional irradiation because it delivers several hundreds of grays in micrometric volumes in few seconds with a particular geometry, which might influence the gene expression response. Due to recent improvements in theoretical and experimental dosimetry [31] experiments involving broad beam irradiation with synchrotron sources are currently in progress in our laboratory to determine the impact of the complex irradiation scheme of MRT. Although a similar study has been done in Boomerang (Melbourne, Australia) [32], the experimental parameters such as the source, the MRT parameters, the tumor model differ than ours.

We determined the pan-genomic response of both tumor and normal brain tissues 6 h after MRT by using microarrays containing 31,000 probesets. In normal brain tissue the expression of about 5% of genes was modified. This proportion is higher than those described using other methods after ionizing irradiation of brain (0.6% 8 h after 10Gy [33], 1.1% and 2.2% 5 h after 10Gy and 20Gy [34]) but is consistent with a previously reported dose-dependent increase in both expression level and number of modulated genes [34–36]. So the unusual number of engaged genes after MRT could be linked to the high dose deposited in tissue, from ~ 18 Gy in valleys to 400Gy in microbeams.

In tumor 1.8% of genes were modified. To our knowledge, no microarray analysis was performed in 9 L after irradiation and those conducted on other high grade glioma models were very different to ours in number of analysed genes, type and dose of irradiation. The unique comparable study applied to MRT was performed on EMT6 subcutaneous mammary tumor [32]. It revealed the modulation of 184 genes but did not address the response of normal tissue.

The response to MRT of normal brain tissues involved 2.7 times more genes than the one of tumor tissue (1,509 versus 554), revealing a tissue-specific response to MRT (Figure 3 and Table S1). Such a higher number of genes could arise from the higher cellular diversity of normal tissue, due to the presence of specific parenchymal and stromal cells such as neurons, astrocytes and oligodendrocytes. Surprisingly these genes were associated with less molecular and cellular functions in normal (18 functions) compared with tumor tissue (22 functions; Figure 5). The 4 supplementary functions in tumor were associated with metabolic processes. However they displayed the lowest statistical significance for tumor response. Responses of both tissues appeared therefore to be close to each other since 18 functions were common. Moreover, a modulation of genes involved in mitosis, cell cycle regulation, apoptosis, cell adhesion, glycolysis, lipid metabolism, has already been reported after ionizing radiation [37] and could be connected to many functions implicated in the response of the both tissue after MRT.

A large number of canonical pathways were also identified 6 h after MRT: 128 and 73 in tumor and contralateral tissues, respectively (Table S2). Among them, 67 were common. More than 90% of canonical pathways found in tumor were also found in brain (only 6 specific pathways out of 73), while 52.3% of normal brain pathways were found in tumor. Thus the tumor response to MRT was mostly included in the brain tissue one. Again, this result could reflect a higher heterogeneity in cell composition and functional processes in normal brain compared to tumor.

Of interest, we observed only one canonical pathway related to brain parenchyma response to MRT (“Huntington’s disease signaling”) which includes genes related to apoptosis (Caspase 1, 3, 7, 8, 12, bax, TP53), intracellular signaling (GNG2, GNG11, CREB3, PRKCH, PRKCD) and one is neuron-specific (CACNA1B). This canonical pathway suggests that some neurons undergo apoptosis in response to MRT.

Among the 67 common pathways to both tissues, immunity and inflammation were widely represented. Modulation of immunity and inflammation has been often reported in brain in response to various stimuli or injuries: Presence of a tumor mass, radiotherapy [38], bacterial or viral infection [39], neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases ([40,41]).

But our results are also in agreement with previous works which reported the immune activation in response to conventional irradiation and even considered irradiation as an “immunological adjuvant” [38,42–44]. Concerning MRT, previous works mainly

focused on vascular parameters to explain therapeutic effect [17]. However increasing leukocytes recruitment was observed in both normal brain [45] and 9 L tumor tissues [17]. Moreover, Sprung *et al.* recently reported that modifications in immunity-related gene expression is a hallmark of response to MRT in mouse mammary tumor [32].

Gasser *et al.* [46] reported that DNA damage can elicit a response of immune system, and in particular of innate compartment (macrophages). But other normal cells constituents can be released into the extracellular compartment during states of cellular stress or damage and subsequently activate inflammation and immunity. Among these Damage-Associated Molecular Patterns, we found HMG1 that is both involved in infectious and sterile inflammation, immune response and tissue repair or regeneration [47]. Receptors such as Toll-like receptors, C-type lectins are sensing these damage-associated mediators. Indeed, we observed a modulation in the expression of several potential mediators and receptors involved in the simulation of inflammation or immunity. For example, HMGB1, Toll-like receptors 1, 2, 7, C-type lectins 7A and CD36 and other altered constituents of irradiated tissue can trigger activation of innate or adaptive cells. These genes may serve as a link between biochemical changes in response to irradiation and the inflammation or immunological challenge.

We evidenced subsequently to this activation that most populations of the immunological compartment were triggered (macrophages, natural killer, dendritic cells, T and B lymphocytes) and many direct crosstalks between cells or diffusible mediators highlighted communication between them.

Dendritic cells constitute the first line of the adaptive immune response, as antigen-presenting cells. Maturation of dendritic cells has been reported to be impaired in cancer in response to tumor-derived mediators, especially the Vascular Endothelial Growth Factor [48]. However the modulation of the pathway “maturation of dendritic cells” in our study suggests that dendritic cell maturation occurred in response to MRT, likely as a part of the “immunological adjuvant” phenomenon discussed above. This would participate in enhancing efficiency of immune control of cancer progression.

We observed also at transcriptomic level the recruitment of innate immune compartment. Presence of Natural killer (NK) was indicated in our study by the modulation of two canonical pathways (“Crosstalk between Dendritic Cells and Natural Killer Cells”, “Tumoricidal Function of Hepatic Natural Killer Cells”) and could be a crucial point for MRT efficiency since NK were previously shown to eliminate 9 L glioma cells both *in vitro* [49] and *in vivo* [50,51].

Among the large spectrum of diffusible mediators, one of them, IL-17 is specifically expressed by T helper 17 cells (Th17; [51]). The presence of these cells was reinforced by modifications in expression of IL-6, IL-23, STAT3, ICOS. These cells are key mediators of a broad array of inflammatory or autoimmune diseases and have been extensively found in tumor microenvironment [52]. But their positive or negative role in tumor progression is still debated. The recruitment of Th17 cells was reported to be triggered by local inflammation at the tumor site [53]. One can

hypothesize that irradiation could increase inflammation and therefore Th17 cell recruitment.

Our transcriptomic results also indicate the presence of cytotoxic T cells (“Cytotoxic T Lymphocyte-mediated Apoptosis of Target Cells”) (Table S2). In parallel with NK cells, cytotoxic T cells were heavily reported in immunological antitumor phenomenon. Cytotoxic T cells have been associated with spontaneous tumoricidal action on glioma and emerged as a part of some therapeutic strategies. For example, vaccination of rats with dendritic cells coinjected with processed GM-CSF secreting 9 L cells triggered the regression of distant 9 L tumors [54]. Treatment efficacy was associated with a Th1 response and thus IFN γ secretion [55]. IFN γ appears also in several canonical pathways modified by MRT in our study (Table S2).

In conclusion to this work we report an extended gene expression profile associated with the MRT responses in both normal and tumor tissues. The early transcriptomic response is very similar in both tissues, mainly involves modifications associated with immunity and inflammation. The detailed study of pathways modulated by MRT reveals the involvement of transcriptomic modification in relation with innate and/or the adaptive immune response. More specifically, pathways and biofunction in link with NK or CD8+ T lymphocytes are particularly represented. Further immunological studies and functional analysis are needed for evaluating the role of those immune mechanisms in the therapeutic impact of irradiation. This is an important step for understanding the biological mechanisms responsible for the therapeutic index of the MRT.

Supporting Information

Table S1 Genes responding significantly to MRT in tumor and normal brain tissues. List of all genes which expression is significantly modified in brain (1,509 genes) and tumor (554 genes). Probesets are ranked for each tissue in descending order of expression MRT/untreated ratio. (XLSX)

Table S2 Canonical pathways constituting the MRT response. All canonical pathways (IPA) found statistically significant with 1% FDR (corresponding to p-value lower than 2.57E-3) are listed for both normal and tumor tissues. (XLSX)

Acknowledgments

We thank the ESRF for ample beamtime and especially Alberto Bravin. We are grateful for scientific and technical help with the following persons: François Berger, Jean Paul Issartel, Raphaël Serduc, Yolanda Prezado and Léonid Rogalev.

Author Contributions

Conceived and designed the experiments: AB GLD LP. Performed the experiments: AB NS MEA CLC EB AM PD PR GLD LP. Analyzed the data: AB NS MEA PR GLD LP. Contributed reagents/materials/analysis tools: AB NS MEA PR GLD LP. Wrote the paper: AB GLD LP.

References

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *Lancet Oncol* 10: 459–466.
2. Slatkin DN, Dilmanian FA, Spanne P (1994) Method for microbeam radiation therapy. 1.
3. Slatkin DN, Spanne P, Dilmanian FA, Sandborg M (1992) Microbeam radiation therapy. *Med Phys* 19: 1395–1400.
4. Archer DW (1998) Collimator for producing an array of microbeams.
5. Slatkin DN, Spanne P, Dilmanian FA, Gebbers JO, Laissue JA (1995) Subacute neuropathological effects of microplanar beams of x-rays from a synchrotron wiggler. *Proc Natl Acad Sci U S A* 92: 8783–8787.

6. Laissue JA, Geiser G, Spanne PO, Dilmanian FA, Gebbers JO, et al. (1998) Neuropathology of ablation of rat gliosarcomas and contiguous brain tissues using a microplanar beam of synchrotron-wiggler-generated X rays. *Int J Cancer* 78: 654–660.
7. Dilmanian FA, Morris GM, Le Duc G, Huang X, Ren B, et al. (2001) Response of avian embryonic brain to spatially segmented x-ray microbeams. *Cell Mol Biol* 47: 485–493.
8. Laissue JA, Blattmann H, Di Michiel M, Slatkin DN, Lyubimova N, et al. (2001) The weaning piglet cerebellum: a surrogate for tolerance to MRT (microbeam radiation therapy) in paediatric neuro-oncology. *Proc. of SPIE*. Washington, Vol. 4508, pp. 65–73.
9. Dilmanian FA, Hainfeld JF, Kruse CA, Cool CD, Sze CI, et al. (2003) Biological mechanisms underlying the X-ray microbeam effects of preferentially destroying tumors. Abstract No. Dilm0599. <http://www.bnl.gov/isd/documents/25005/Abstracts/dilm0599.pdf>. *Natl Synchrotron Light Source Act Rep 2002 MA Corwin SN Ehrlich Eds*.
10. Miura M, Blattmann H, Bräuer-Krisch E, Bravin A, Hanson AL, et al. (2006) Radiosurgical palliation of aggressive murine SCCVII squamous cell carcinomas using synchrotron-generated X-ray microbeams. *Br J Radiol* 79: 71–75. doi:10.1259/bjr/50464795.
11. Dilmanian FA, Button TM, Le Duc G, Zhong N, Pena LA, et al. (2002) Response of rat intracranial 9 L gliosarcoma to microbeam radiation therapy. *Neuro-Oncol* 4: 26–38.
12. Regnard P, Duc GL, Bräuer-Krisch E, Tropes I, Siegbahn EA, et al. (2008) Irradiation of intracerebral 9 L gliosarcoma by a single array of microplanar x-ray beams from a synchrotron: balance between curing and sparing. *Phys Med Biol* 53: 861–868.
13. Bouchet A, Boumendjel A, Khalil E, Serduc R, Brauer E, et al. (2012) Chalcone JAI-51 improves efficacy of synchrotron microbeam radiation therapy of brain tumors. *J Synchrotron Radiat* 19: 478–482.
14. Serduc R, van de Looij Y, Franconi G, Verdonck O, van der Sanden B, et al. (2008) Characterization and quantification of cerebral edema induced by synchrotron x-ray microbeam radiation therapy. *Phys Med Biol* 53: 1153–1166.
15. Serduc R, Verant P, Vial JC, Farion R, Rocas L, et al. (2006) In vivo two-photon microscopy study of short-term effects of microbeam irradiation on normal mouse brain microvasculature. *Int J Radiat Oncol Biol Phys* 64: 1519–1527.
16. Serduc R, Christen T, Laissue J, Farion R, Bouchet A, et al. (2008) Brain tumor vessel response to synchrotron microbeam radiation therapy: a short-term in vivo study. *Phys Med Biol* 53: 3609–3622. doi:S0031-9155(08)68169-5 [pii] 10.1088/0031-9155/53/13/015.
17. Bouchet A, Lemasson B, Leduc G, Maisin C, Bräuer-Krisch E, et al. (2010) Preferential effect of synchrotron microbeam radiation therapy on intracerebral 9 L gliosarcoma vascular networks. *Int J Rad Onc Biol Phys* 78: 1503–1512.
18. Crosbie JC, Anderson RL, Rothkamm K, Restall CM, Cann L, et al. (2010) Tumor cell response to synchrotron microbeam radiation therapy differs markedly from cells in normal tissues. *Int J Radiat Oncol Biol Phys* 77: 886–894. doi:S0360-3016(10)00135-5 [pii] 10.1016/j.ijrobp.2010.01.035.
19. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, et al. (1996) Use of a cDNA microarray to analyse gene expression patterns in human cancer. *Nat Genet* 14: 457–460.
20. Benda P, Someda K, Messer J, Sweet WH (1971) Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture. *J Neurosurg* 34: 310–323.
21. Régnard P, Bräuer-Krisch E, Tropès I, Keyriläinen J, Bravin A, et al. (2008) Enhancement of survival of 9 L gliosarcoma bearing rats following intracerebral delivery of drugs in combination with microbeam radiation therapy. *Eur J Radiol* 68: S151–5. doi:10.1016/j.ejrad.2008.04.049.
22. Bräuer-Krisch E, Bravin A, Lerch M, Rosenfeld A, Stepanek J, et al. (2003) MOSFET dosimetry for microbeam radiation therapy at the European Synchrotron Radiation Facility. *Med Phys* 30: 583–589.
23. Bräuer-Krisch E, Requardt H, Brochard T, Berruyer G, Renier M, et al. (2009) New technology enables high precision multislit collimators for microbeam radiation therapy. *Rev Sci Instrum* 80: 074301.
24. Salvat F, Fernández-Varea JM, Sempau J, Organització de Cooperació i Desenvolupament Econòmic, editors(2009) PENELOPE 2008: A code system for Monte Carlo simulation of electron and photon transport: workshop proceedings, Barcelona, Spain 30 June–3 July 2008. Paris: OECD.
25. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. *Biostat Oxf Engl* 4: 249–264.
26. Liu W, Mei R, Di X, Ryder TB, Hubbell E, et al. (2002) Analysis of high density expression microarrays with signed-rank call algorithms. *Bioinforma Oxf Engl* 18: 1593–1599.
27. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. *Proc Natl Acad Sci U S A* 98: 5116–5121.
28. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I (2001) Controlling the false discovery rate in behavior genetics research. *Behav Brain Res* 125: 279–284.
29. Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. *Proc Natl Acad Sci U S A* 100: 9440–9445.
30. Barth RF, Kaur B (2009) Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. *J Neurooncol* 94: 299–312. doi:10.1007/s11060-009-9875-7.
31. Prezado Y, Martinez-Rovira I, Thengumpallil S, Deman P (2011) Dosimetry protocol for the preclinical trials in white-beam minibeam radiation therapy. *Med Phys* 38: 5012–5020.
32. Sprung CN, Yang Y, Forrester HB, Li J, Zaitseva M, et al. (2012) Genome-wide transcription responses to synchrotron microbeam radiotherapy. *Radiat Res* 178: 249–259.
33. Zhao W, Chuang EY, Mishra M, Awwad R, Bisht K, et al. (2006) Distinct effects of ionizing radiation on in vivo murine kidney and brain normal tissue gene expression. *Clin Cancer Res Off J Am Assoc Cancer Res* 12: 3823–3830.
34. Mahmoud-Ahmed AS, Atkinson S, Wong CS (2006) Early gene expression profile in mouse brain after exposure to ionizing radiation. *Radiat Res* 165: 142–154.
35. Yin E, Nelson DO, Coleman MA, Peterson LE, Wyrobek AJ (2003) Gene expression changes in mouse brain after exposure to low-dose ionizing radiation. *Int J Radiat Biol* 79: 759–775.
36. Shin SC, Lee KM, Kang YM, Kim K, Lim SA, et al. (2011) Differential expression of immune-associated cancer regulatory genes in low- versus high-dose-rate irradiated AKR/J mice. *Genomics* 97: 358–363.
37. Boerma M, van der Wees CGC, Vrieling H, Svensson JP, Wondergem J, et al. (2005) Microarray analysis of gene expression profiles of cardiac myocytes and fibroblasts after mechanical stress, ionising or ultraviolet radiation. *BMC Genomics* 6: 6.
38. Demaria S, Formenti SC (2012) Radiation as an immunological adjuvant: current evidence on dose and fractionation. *Front Oncol* 2: 153.
39. Peterson KE, Du M (2009) Innate immunity in the pathogenesis of polytropic retrovirus infection in the central nervous system. *Immunol Res* 43: 149–159. doi:10.1007/s12026-008-8060-y.
40. Fung A, Vizcaychipi M, Lloyd D, Wan Y, Ma D (2012) Central nervous system inflammation in disease related conditions: mechanistic prospects. *Brain Res* 1446: 144–155. doi:10.1016/j.brainres.2012.01.061.
41. Amor S, Puentes F, Baker D, van der Valk P (2010) Inflammation in neurodegenerative diseases. *Immunology* 129: 154–169. doi:10.1111/j.1365-2567.2009.03225.x.
42. Multhoff G, Radons J (2012) Radiation, inflammation, and immune responses in cancer. *Front Oncol* 2: 58.
43. Desmarais G, Fortin D, Bujold R, Wagner R, Mathieu D, et al. (2012) Infiltration of glioma cells in brain parenchyma stimulated by radiation in the F98/Fischer rat model. *Int J Radiat Biol* 88: 565–574.
44. Kureshi SA, Hofman FM, Schneider JH, Chin LS, Apuzzo ML, et al. (1994) Cytokine expression in radiation-induced delayed cerebral injury. *Neurosurgery* 35: 822–9; discussion 829–30.
45. Serduc R, Brauer-Krisch E, Siegbahn EA, Bouchet A, Pouyatos B, et al. (2010) High-precision radiosurgical dose delivery by interlaced microbeam arrays of high-flux low-energy synchrotron X-rays. *PLoS One* 5: e9028. doi:10.1371/journal.pone.0009028.
46. Gasser S, Orsulic S, Brown EJ, Raulet DH (2005) The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. *Nature* 436: 1186–1190.
47. Klune JR, Dhupar R, Cardinal J, Billiri TR, Tsung A (2008) HMGB1: endogenous danger signaling. *Mol Med Camb Mass* 14: 476–484.
48. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, et al. (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. *Nat Med* 2: 1096–1103.
49. Shimizu K, Adachi K, Teramoto A (2005) Growth hormone enhances natural killer cell activity against glioma. *J Nippon Med Sch Nippon Ika Daigaku Zasshi* 72: 335–340.
50. Witham TF, Villa L, Yang T, Pollack IF, Okada H, et al. (2003) Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9 L gliosarcoma in vivo. *J Neurooncol* 64: 63–69.
51. Harrington LE, Mangan PR, Weaver CT (2006) Expanding the effector CD4 T-cell repertoire: the Th17 lineage. *Curr Opin Immunol* 18: 349–356. doi:10.1016/j.coi.2006.03.017.
52. Ye J, Livergood RS, Peng G (2013) The role and regulation of human Th17 cells in tumor immunity. *Am J Pathol* 182: 10–20.
53. Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, et al. (2010) Tumor microenvironments direct the recruitment and expansion of human Th17 cells. *J Immunol Baltim Md* 1950 184: 1630–1641.
54. Driessens G, Hamdane M, Cool V, Velu T, Bruyns C (2004) Highly successful therapeutic vaccinations combining dendritic cells and tumor cells secreting granulocyte macrophage colony-stimulating factor. *Cancer Res* 64: 8435–8442. doi:10.1158/0008-5472.CAN-04-0774.
55. Driessens G, Gordower L, Nuttin L, Stordeur P, Blocklet D, et al. (2008) Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltration. *Cancer Immunol Immunother* 57: 1745–1756. doi:10.1007/s00262-008-0500-y.